Genmab — Juni 2020

[gentogen]

Sprøjt

[E_L]

https://twitter.com/DocHutchings/status/1271422728604659717

[Bulder]

No news as far as I can see

[gentogen]

Så vidt jeg kan tyde det, står der data cut off for efficacy var 14. maj (så kun få dage mere end sidst)

[gentogen]

Fra Roche: https://www.roche.com/dam/jcr:148d9556-2384-4399-8768-2e59aec09dc1/en/200612-ir-glofitamab-eha-stage3-approved.pdf

[E_L]

OR for DLBCL now 60%, was 50% , 1 more patient (15 vs 14)

[E_L]

and
1 patient went from Stable disease to Partial response

[E_L]

it also says "the emerging favourable safety profile of epcoritamab suggests that it has the potential for outpatient administration"

[E_L]

that would be fantastic

[Mcjean]

Tell it to the insulted danish banks, maybe they will raise stockprice with 10 kr.

[Bulder]

But glofitamab's CR-rates look impressive.

[Bulder]

Median prior lines = 3 for both

[E_L]

yes. even though a bit more toxic?

[E_L]

and it seems higher dose for glofitamab do not make a lot of difference?

[E_L]

hopefully for epco it does. only 4 patients in figure 4 at the 48mg so far and i assume they have been on that for the shortest time (compared to others)

[Solsen]

Yes thats the question. But normally higher dose more effective and more toxic. But I couldnt se that clearely in recent data. Small group and hard to se.

[E_L]

well if it is true that they will start 10 epco trials we will have a lot of data to look forward to lol

[E_L]

I wonder if we are going to repeat the whole Dara experience again...

[StockBull]

nyt TA signal https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/84651_nyt_genmab_signal.JPG

[Bulder]

I suppose the expansion part will be ready for ASH